Introduction:
Prominent contract development and manufacturing organization (CDMO), Biovian Oy, known for its expertise in biopharmaceuticals, announces a significant upgrade to its Turku manufacturing facility.
Features:
The forthcoming facility will occupy a spacious area of 6,400 sqm (69,000 sqft) and will be equipped with state-of-the-art technology to support the development, production, and testing of Advanced Therapy Medicinal Products (ATMP), which includes therapies like adenoviral and AAV therapies.
The facility's design includes segregated cleanroom zones ranging from Class A to D, ensuring compliance with rigorous manufacturing standards such as current good manufacturing practices (cGMP), EU, and US GMP regulations.
Coupled with Biovian's existing manufacturing setup, the new expansion will extend the overall facility area to 11,500 sqm (123,800 sqft), bolstering capacity and flexibility for larger-scale projects involving viral vectors and microbial proteins.
Approximately 100 employment opportunities are expected to be generated by this investment, augmenting Biovian's current workforce, which stands at around 200.
The expansion initiative is projected to conclude by December 2024, with the new facility anticipated to be fully operational by 2025.
Specifications:
Name: Biovian
Type: Expansion
Year: 2025
